Domestic bio companies developing new drugs are shifting to a full-fledged profit-generating structure through technology exports and sales of their own new drugs. Unlike in the past, when it was common to post losses for a long period after listing, there have recently been a series of cases in which companies turn a profit in the first year of listing or renew record-high earnings. The assessment is that the bio industry, long regarded as a research and development-centered sector, is moving into a stage where it generates tangible profits.


The quality of earnings is also improving as upfront payments and milestone revenues from technology transfer, along with sales of proprietary drugs, are all reflected at the same time. Analysts say a virtuous cycle is beginning to take hold, in which research achievements lead to cash flow, and this capital is then reinvested into follow-up pipelines. However, some point out that, going forward, it will be necessary to evolve beyond simple technology transfer into collaborative models that share development risks and know-how with global pharmaceutical companies.

How New Drug Bio Firms Are Stealing the Spotlight...How to Make the Most of This Rare Opportunity View original image

Meanwhile, interest in stock loans is growing by the day. This is because investors who do not want to miss rare investment opportunities are turning their attention to stock loans, which allow them to use more funds to purchase stocks.


Another advantage of stock loans is that even if investors using margin or credit trading face a forced liquidation crisis due to a sharp stock price drop, they can simply switch over without providing additional collateral or selling their holdings, and then wait for a rebound.


◆ All New Stock Loan, from products with the lowest annual interest rate in the 5% range to products exempt from DSR!

All New Stock Loan has launched a securities-linked credit product with the industry's lowest interest rate in the annual 5% range so that any investor can use stock loans without burden. It can be used not only for stock purchases but also for same-day refinancing of margin or credit loans from securities firms, and up to four times the investor's own capital can be utilized regardless of credit rating.


In addition, All New Stock Loan offers products that are not affected by the DSR limit for investors who previously had difficulty using stock loans due to DSR restrictions. Investors using the alternative trading system (NXT) can also use these services.


Investors who want to know more about All New Stock Loan can contact the customer service center (☎1599-8666) and conveniently consult with a professional counselor at any time, regardless of whether they ultimately take out a loan.


○ Product launched with the industry's lowest annual interest rate in the 5% range!

○ Regardless of existing loan balance or income! (Not subject to DSR)

○ Ability to use up to four times your own capital as stock investment funds! (Including your own funds)

○ Same-day immediate refinancing of securities credit/margin positions available!

○ Trading on the alternative trading system (NXT) available

○ Even stocks that were difficult to purchase with existing securities firm credit or stock loans are OK!

* All New Stock Loan Customer Service Center: 1599-8666

Direct link: https://allnewstockloan.co.kr?agency=HTS


Hanwha Ocean, Hanwha Systems, Hyulim Robot, AprilBio, Alteogen



※ The above content is unrelated to the editorial direction of The Asia Business Daily, and all responsibility lies with the information provider.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing